- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Petros Pharmaceuticals files $100M mixed securities shelf | 1 | Seeking Alpha | ||
| 23.04. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health | 305 | ACCESSWIRE | Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patients(Please see important safety information below)NEW YORK, NY / ACCESSWIRE... ► Artikel lesen | |
| 16.04. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA | 190 | ACCESSWIRE | (Please see important safety information below)NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding consumer... ► Artikel lesen | |
| 02.04. | Petros Pharma Stock Down, Despite Positive Results For Stendra Study | 1 | RTTNews | ||
| 02.04. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection Study for STENDRA as it Pursues OTC Status | 223 | ACCESSWIRE | Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56%... ► Artikel lesen | |
| 01.04. | Petros Pharmaceuticals, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
| 22.03. | Petros Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.03. | Petros Pharmaceuticals launches AI tool for STENDRA OTC study | 1 | Investing.com | ||
| 19.03. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider | 234 | ACCESSWIRE | Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC Status(Please... ► Artikel lesen | |
| 14.02. | Petros Pharmaceuticals partners with AI firm for new OTC medication | 3 | Investing.com | ||
| 14.02. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider | 641 | ACCESSWIRE | AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counterNEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc.... ► Artikel lesen | |
| 24.01. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA Rx-to-OTC Switch | 388 | ACCESSWIRE | FDA requests meeting to review the Company's technology component and discuss further development and requirementsNEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)... ► Artikel lesen | |
| 18.01. | NCAC, PTPI and CTSO among pre-market losers | 1 | Seeking Alpha | ||
| 17.01. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA Rx-to-OTC Switch | 313 | ACCESSWIRE | Over 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward STENDRA® working to become the first erectile dysfunction... ► Artikel lesen | |
| 12.01. | Petros Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.12.23 | Petros Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.12.23 | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA the First Erectile Dysfunction Medication to Achieve OTC Status | 330 | ACCESSWIRE | Human Factor Study represents important component of FDA requirements for technology to pave way for STENDRA OTC approvalNEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc.... ► Artikel lesen | |
| 12.12.23 | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's OTC Switch Technology Provider | 267 | ACCESSWIRE | Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch ApprovalNEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)... ► Artikel lesen | |
| 05.12.23 | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's OTC Switch Technology Provider | 393 | ACCESSWIRE | Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch ApprovalNEW YORK, NY / ACCESSWIRE / December 5, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)... ► Artikel lesen | |
| 15.11.23 | Petros Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 22,200 | -1,77 % | MPH Health Care steigert 2023 Net Asset Value je Aktie | MPH Health Care meldet für das Jahr 2023 einen Anstieg des Net Asset Values von 51,72 Euro je Aktie auf 58,62 Euro. Vor Zinsen und Steuern hat die Berliner Investmentgesellschaft das Ergebnis von 29... ► Artikel lesen | |
| DIGICANN VENTURES | 0,016 | +52,38 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 26.01.2024 | The following instruments on XETRA do have their first trading 26.01.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 26.01.2024
Aktien
1 KYG7006A1094 Perfect Corp.
2 JP3501950004... ► Artikel lesen | |
| FSD PHARMA | 0,328 | -3,11 % | FSD Pharma Inc.: FSD Pharma Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd in an Induced State of Alcohol Intoxication | TORONTO, ON / ACCESSWIRE / April 30, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" of the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative... ► Artikel lesen | |
| DMK PHARMACEUTICALS | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 2 | The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameLU0102219945 G.SACHS... ► Artikel lesen | |
| IONIC BRANDS | 0,005 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.04.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2024ISIN NameAU000000AC89 AUSCANN... ► Artikel lesen | |
| QUALIGEN THERAPEUTICS | 0,232 | -3,33 % | Marizyme Inc.: Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft | JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the "Agreement") with Qualigen Therapeutics... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,250 | -0,71 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis | - ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports "Soft" Topical JAK Inhibitor Approach - - ATI-1777... ► Artikel lesen | |
| BIOSTAR PHARMACEUTICALS | - | - | US FDA grants orphan drug designation to Biostar Pharma's utidelone | ||
| BAUDAX BIO | 0,184 | -1,24 % | Delisting of Securities of Sono Group N.V.; Baudax Bio, Inc.; Comera Life Sciences Holdings, Inc.; Missfresh Limited; Rose Hill Acquisition Corporation; Axcella Health; Zivo Bioscience, Inc.; Sonic Foundry, Inc.; Mobiquity Technologies, Inc. and others | NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common shares of Sono Group N.V. Sono Group N.V.'s securities were suspended on July 21, 2023... ► Artikel lesen | |
| BAYER | 28,020 | -0,39 % | Dividendenbekanntmachungen (29.04.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 361 DEGREES INTERNATIONAL LTD KYG884931042 0,139 HKD 0,0166 EUR ACROW LIMITED AU0000006124 0,0285 AUD 0,0174 EUR AGNC INVESTMENT... ► Artikel lesen | |
| MERCK KGAA | 152,00 | +1,13 % | Merck KGaA-Aktie: Kurs klettert leicht (153,15 €) | Im Plus liegt gegenwärtig die Aktie von Merck . Zuletzt zahlten Investoren für die Aktie 153,15 Euro. Heute hat sich am deutschen Aktienmarkt das Wertpapier von Merck zwischenzeitlich um 1,90 Prozent... ► Artikel lesen | |
| NOVO NORDISK | 114,02 | -2,21 % | Novo Nordisk vor Zahlen: Das erwarten die Analysten | Europas wertvollstes börsennotiertes Unternehmen öffnet am Donnerstag in dieser Handelswoche (02. Mai) seine Bücher zum ersten Quartal. DER AKTIONÄR zeigt auf, was die Analysten im Durchschnitt vom... ► Artikel lesen | |
| CANOPY GROWTH | 9,500 | +0,21 % | Breaking News: Marihuana-Hammer - Tilray, Curaleaf, Canopy & Co explodieren | Das kommt überraschend: In Amerika ändert sich die Einschätzung von Marihuana. Die Drogenbehörde DEA ändert ihre Einstufung von Marihuana auf Schedule III. Damit erkennt sie die medizinische Verwendung... ► Artikel lesen | |
| ASTRAZENECA | 140,80 | -0,56 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca mit einem Kursziel von 13000 Pence auf "Overweight" belassen. Die Resultate für das Mittel Enhertu aus der DB06-Brustkrebs-Studie... ► Artikel lesen | |
| ELI LILLY | 684,60 | +0,16 % | Vor den Earnings: Verhageln die Engpässe bei der Abnehmspritze die Earnings für Eli Lilly? | © Foto: Sascha Lotz/dpaDer Erfolg der begehrten Blockbuster Mounjaro und Zepbound könnte Eli Lilly zum Verhängnis werden und für eine negative Überraschung bei den Quartalszahlen sorgen. US-Pharmariese... ► Artikel lesen |
PETROS PHARMACEUTICALS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,033 (+4,91 %) liegt der Kurs bei 0,713 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
